 |
|
NMP22 and Surveillance for Recurrent Bladder Cancer—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: In this study comparing the NMP22 point-of-care assay with cytology for detection of recurrent bladder cancer, both tests were compared with cystoscopy. Cystoscopy was performed in all patients at baseline and surveillance was performed according to the practice of the urologists participating in the study. All patients continued to have cystoscopic surveillance at various intervals, and follow-up cystoscopy data for all patients were reviewed for the first poststudy evaluation. Although cystoscopy is the standard for diagnosing bladder cancer, it is flawed and fails to detect some cancers.1 This makes the determination of false-positive tests more difficult.
Nine patients were found to have bladder tumors between 1 and 5 months after the baseline cystoscopy. Three had significant disease 1 month later (1 T2 and 2 Tis), and all of these 3 were identified by the NMP22 test. These tumors were almost certainly present at the time of the earlier . . . [Full Text of this Article]
H. Barton Grossman, MD
hbgrossman@mdanderson.org
Department of Urology
M. D. Anderson Cancer Center
Houston, Tex
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
NMP22 and Surveillance for Recurrent Bladder Cancer
Chad T. Wilson
JAMA. 2006;296(1):44-45.
EXTRACT
| FULL TEXT
NMP22 and Surveillance for Recurrent Bladder Cancer
Scott Eggener and Harry Herr
JAMA. 2006;296(1):45.
EXTRACT
| FULL TEXT
Surveillance for Recurrent Bladder Cancer Using a Point-of-Care Proteomic Assay
H. Barton Grossman, Mark Soloway, Edward Messing, Giora Katz, Barry Stein, Vahan Kassabian, and Yu Shen
JAMA. 2006;295(3):299-305.
ABSTRACT
| FULL TEXT
|
